US20140186461A1 - Human Amniotic Membrane Lyophilized Grafts - Google Patents
Human Amniotic Membrane Lyophilized Grafts Download PDFInfo
- Publication number
- US20140186461A1 US20140186461A1 US13/608,475 US201213608475A US2014186461A1 US 20140186461 A1 US20140186461 A1 US 20140186461A1 US 201213608475 A US201213608475 A US 201213608475A US 2014186461 A1 US2014186461 A1 US 2014186461A1
- Authority
- US
- United States
- Prior art keywords
- tissue
- damaged
- amniotic membrane
- graft
- layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000001691 amnion Anatomy 0.000 title claims abstract description 42
- 210000002826 placenta Anatomy 0.000 claims abstract description 20
- 230000001954 sterilising effect Effects 0.000 claims abstract description 4
- 210000001519 tissue Anatomy 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 31
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 210000005059 placental tissue Anatomy 0.000 claims description 4
- 210000002435 tendon Anatomy 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 210000002950 fibroblast Anatomy 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 210000002469 basement membrane Anatomy 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 210000000981 epithelium Anatomy 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims 3
- 210000005003 heart tissue Anatomy 0.000 claims 3
- 210000004877 mucosa Anatomy 0.000 claims 3
- 238000004806 packaging method and process Methods 0.000 claims 2
- 238000004140 cleaning Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 abstract description 9
- 238000004108 freeze drying Methods 0.000 abstract description 8
- 238000003860 storage Methods 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 6
- 230000004071 biological effect Effects 0.000 abstract description 6
- 230000018044 dehydration Effects 0.000 abstract description 3
- 238000006297 dehydration reaction Methods 0.000 abstract description 3
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 3
- 210000004291 uterus Anatomy 0.000 abstract description 2
- 239000010410 layer Substances 0.000 description 13
- 238000007689 inspection Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000001136 chorion Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 210000002219 extraembryonic membrane Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000011088 parchment paper Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009677 vaginal delivery Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/3645—Connective tissue
- A61L27/3662—Ligaments, tendons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/3679—Hollow organs, e.g. bladder, esophagus, urether, uterus, intestine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/10—Materials or treatment for tissue regeneration for reconstruction of tendons or ligaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
Definitions
- Human amniotic membrane derived from the placenta has been used for nearly 100 years as a transplantable biomaterial for the surgical reconstruction of various tissues in the human body.
- Such a membrane has been utilized widely in the management of ocular surface disorders; utilized as a biological dressing or graft for skin (burns, skin wounds, skin ulcers); utilized to prevent tissue adhesion in surgical procedures of the spine, abdomen and pelvis; utilized as a wrap for tendon and nerve repair procedures; and utilized as a graft for dental/oral procedures.
- a membrane has is either dehydrated or cryopreserved prior to storage until ready for surgical transplantation.
- the placental tissue, from which the amniotic membrane is derived, is harvested after birth or after elective Cesarean section surgery.
- the fetal membranes of the placenta are comprised of two principal layers: (1) the outer chorion layer which is in contact with maternal cells and forms the outer aspect of the sac, and (2) the inner amniotic membrane layer which contains large amounts of collagen and is bathed by amniotic fluid contained within the sac.
- the amniotic membrane is a thin, translucent, elastic tissue which forms the innermost layer of the amniotic sac and the placenta.
- the amniotic membrane is comprised of 3 layers ( FIG. 2 ): an epithelial monolayer, a basement membrane and stroma.
- the stroma can be further subdivided into a compact layer, a fibroblast layer containing a loose network of fibroblasts, and a spongy layer.
- amniotic membranes which are dehydrated via a lyophilized (freeze dried) method without using heat or chemicals to hereby better preserve the naturally occurring biological properties of the amniotic membrane seen in nature.
- Such grafts when properly prepared, can be stored at ambient temperatures for prolonged periods of time until ready for transplantation while maintaining the histologic and biological properties seen in utero.
- Amnion membrane as a tissue graft provides a natural biological barrier, a matrix for cell migration and proliferation, and naturally occurring growth factors and other biological components that contribute to healing at the site of transplantation.
- Such a membrane when transplanted has the added benefit of the absence of immune rejection due to the lack of most of the major histocompatibility (HLA) antigens and viable cells.
- HLA major histocompatibility
- Described herein are human tissue grafts derived from the placenta comprised of the amniotic membrane which is processed using physiologic solutions, lyophilization and terminal sterilization (via gamma irradiation in a frozen state) that thereby preserves the graft in such a manner as to retain the naturally occurring biological properties of the amniotic membrane and offer a sterile graft for transplantation.
- the graft has the advantage of storage at ambient temperatures for prolonged periods of time prior to transplantation.
- the advantage of this invention is that it solves the problem existing for the cryopreserved grafts, namely, the need for refrigeration or frozen storage of the graft in a wet state.
- This invention also solves the problem existing for the heat/chemical dried grafts, namely, the deprived biological properties remaining in a graft that has been dehydrated using heat and chemicals and/or the removal of the epithelium layer.
- FIG. 1 is a process overview flowchart for the recovery and manufacture of the tissue grafts described herein.
- FIG. 2 is an exemplary histological representation sketch of the layers of the tissue grafts.
- FIG. 1 depicts a process overview flowchart for the recovery and manufacture of the tissue grafts described herein.
- Step 1 Informed Consent Obtained, Donor Pre-Screened for Eligibility and Suitability
- the potential female donor is approached and written informed consent is obtained following standard industry practices and the guidelines set forth by AATB.
- the potential donor must fully understand the donation process and give their informed consent to the process and to the testing of their blood for diseases that may affect the suitability of their placenta tissues for use.
- the donor After written consent is obtained, the donor is pre-screened for eligibility and suitability to donate her placenta at delivery. Screening involves assessment for risk factors to communicable diseases as specified in the Food and Drug Administration's (FDA) Donor Eligibility Guidance documents and regulations for Good Tissue Practices (GTP) for human tissue products intended for human transplantation. Additionally, standards put forth by the American Association of Tissue Banks (AATB) are also used as guidelines for donor eligibility criteria. After initial pre-screening information is reviewed, a determination is made as to whether the donor is eligible to donate and plans are made for the recovery of the placenta upon delivery.
- FDA Food and Drug Administration's
- GTP Good Tissue Practices
- AATB American Association of Tissue Banks
- Step 2 Recover Placenta for Donor Meeting Pre-Screening Criteria
- the recovery of the placenta takes place in a hospital or birthing center where it is collected during a live Cesarean section or vaginal delivery birth.
- the placenta is recovered by the operating room or delivery personnel and placed in sterile designated containers, labeled with distinct donor identification information.
- the packaged placenta is then either shipped on wet or dry ice to the processing facility or it is temporarily stored in a freezer until it can be shipped to the processing facility.
- Step 3 Test Donor Blood for Infectious Diseases per Criteria
- Blood samples are drawn from the donor within 7 days before or after delivery and sent to a CLIA accredited contract laboratory to be tested for communicable diseases such as hepatitis, AIDS, Syphilis, and West Nile Virus using FDA licensed test kits, where appropriate.
- communicable diseases such as hepatitis, AIDS, Syphilis, and West Nile Virus using FDA licensed test kits, where appropriate.
- the specific list of tests for these communicable diseases that are performed are per the current FDA Donor Eligibility and GTP requirements and per AATB's standards.
- Step 4 Inspect & Release Placenta If/When All Critiera Met
- the placenta container is inspected at the processing facility upon receipt. All donor medical history charts are compiled and reviewed to include completed behavioral, sexual, medical, clinical, and health questionnaires, results of serology testing for communicable diseases, pre-natal history and medical records and hospital/birthing center delivery records. Once all donor criteria are met, the placenta is released for processing.
- Step 5 Process Tissue to Separate Amnion
- the placenta is thawed (if previously frozen) in a controlled environment and all processing methods are conducted in a controlled environment following FDA's GTP and AATB standards. Equipment and the facilities used are cleaned and decontaminated and all major processing steps are documented following industry practice, FDA regulations and AATB standards. Critical processes are validated per FDA requirements. Work areas are draped prior to usage and supplies and instruments are either sterile or clean with known manufacturing methods to control incoming bioburden.
- Placenta is inspected for abnormalities and pre-processing samples are taken to determine the baseline Bioburden.
- Placentas passing inspection are further processed by separating the amnion layers from both sides of the placenta from the chorion layers and the rest of the placenta.
- the isolated amnion layers in the form of continuous sheets of tissue are then further processed.
- Step 6 Soak, Rinse & Clean Amnion with Physiologic Saline Solutions
- the isolated amnion sheets are further processed by briefly soaking for up to 1 hour at room temperature in a physiologic saline solution such as Earle's Balanced Salt Solution (1 ⁇ ) or Hank's Balanced Salt Solution (1 ⁇ ) with periodic gentle mixing to disassociate blood from the amnion. During this time, multiple subsequent rinses with Earle's or Hank's, as needed, may be performed to further remove the blood during the soak time. During or upon completion of the soak and rinse processes, any remaining blood clots or blood on the surface of the amnion may be manually removed. The resultant amnion sheets are now ready for lyophilization.
- a physiologic saline solution such as Earle's Balanced Salt Solution (1 ⁇ ) or Hank's Balanced Salt Solution (1 ⁇ ) with periodic gentle mixing to disassociate blood from the amnion.
- multiple subsequent rinses with Earle's or Hank's may be performed to further remove the blood during the soak time.
- Step 7 Lyophilize (Freeze Dry)
- amnion sheets are spread out on parchment paper with the stromal side face down, placed on lyophilization trays, placed in sealed lyophilization bags and lyophilized at approximately ⁇ 40 to ⁇ 45° C. for 20-48 hours using standard lyophilization methods until moisture is removed and desired drying is achieved. Freeze dry time may vary depending on the thickness of the tissue and the size of the amnion sheets.
- Step 8 Cut, Section & Package
- the freeze dried (lyophilized) amnion sheets are sectioned into desired sizes (e.g. 4 cm ⁇ 4 cm, 4 cm ⁇ 6 cm, etc.) using any sharp cutting device (e.g. a scalpel, a device similar to a pizza cutter, etc.), packaged and sealed (e.g. heat sealed, vacuum sealed, etc.).
- any sharp cutting device e.g. a scalpel, a device similar to a pizza cutter, etc.
- packaged and sealed e.g. heat sealed, vacuum sealed, etc.
- Step 9 Inspect & Test
- Routine quality inspections of each unit are performed to ensure that manufacturing criteria are met in the areas of size, appearance, package integrity, etc.
- Standard residual moisture tests may be performed on random units to ensure consistency of the freeze drying process.
- Step 10 Sterilize—Gamma Irradiate Amniotic Membrane While Frozen
- the lyophilized amnion products are shipped to a contract sterilizer to be gamma irradiated by a validated method to achieve a Sterility Assurance Level (SAL) of 10-6.
- SAL Sterility Assurance Level
- the gamma irradiation is performed on dry ice with product in the frozen state to circumvent damage to the tissue.
- Sterilized product is returned to the possession of the processor for a final inspection.
- Sterilized product returned from the contract sterilizer is inspected at by the processing facility for final release. Inspection will include package integrity inspection and final labeling inspection, to name a few. Units passing inspection are released for storage, distribution and subsequent transplantation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Pregnancy & Childbirth (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
Described herein are human amniotic membrane tissue grafts derived from the placenta. The grafts are composed of three layers as seen in the amniotic membrane in utero. These grafts are processed using physiologic solutions, lyophilized and terminal sterilized (via gamma irradiation in a frozen state) that thereby preserves the graft in such a manner as to retain the naturally occurring biological properties of the amniotic membrane and offer a sterile graft for transplantation. By dehydration via lyophilization and terminal sterilization, the graft has the advantage of storage at ambient temperatures for prolonged periods of time prior to transplantation.
Description
- Not Applicable
- Not Applicable
- Not Applicable
- Not Applicable
- Human amniotic membrane derived from the placenta has been used for nearly 100 years as a transplantable biomaterial for the surgical reconstruction of various tissues in the human body. Such a membrane has been utilized widely in the management of ocular surface disorders; utilized as a biological dressing or graft for skin (burns, skin wounds, skin ulcers); utilized to prevent tissue adhesion in surgical procedures of the spine, abdomen and pelvis; utilized as a wrap for tendon and nerve repair procedures; and utilized as a graft for dental/oral procedures. Normally, such a membrane has is either dehydrated or cryopreserved prior to storage until ready for surgical transplantation.
- The placental tissue, from which the amniotic membrane is derived, is harvested after birth or after elective Cesarean section surgery. At full term of gestation, the fetal membranes of the placenta are comprised of two principal layers: (1) the outer chorion layer which is in contact with maternal cells and forms the outer aspect of the sac, and (2) the inner amniotic membrane layer which contains large amounts of collagen and is bathed by amniotic fluid contained within the sac. The amniotic membrane is a thin, translucent, elastic tissue which forms the innermost layer of the amniotic sac and the placenta. Histologically, the amniotic membrane is comprised of 3 layers (
FIG. 2 ): an epithelial monolayer, a basement membrane and stroma. The stroma can be further subdivided into a compact layer, a fibroblast layer containing a loose network of fibroblasts, and a spongy layer. - There are storage challenges with the amniotic membrane in the cryopreserved forms as this requires refrigeration or freezing to maintain these tissue grafts. The dried forms of the amniotic membrane has a storage advantage however, the methods of drying/dehydration involve the use of heat, chemicals and sometimes the removal of the epithelial layer which renders an altered histologic profile and contributes to the destruction or reduction of the naturally occurring biological properties of the amniotic membrane as seen in nature. Described herein are amniotic membranes which are dehydrated via a lyophilized (freeze dried) method without using heat or chemicals to hereby better preserve the naturally occurring biological properties of the amniotic membrane seen in nature. Such grafts, when properly prepared, can be stored at ambient temperatures for prolonged periods of time until ready for transplantation while maintaining the histologic and biological properties seen in utero.
- Amnion membrane as a tissue graft provides a natural biological barrier, a matrix for cell migration and proliferation, and naturally occurring growth factors and other biological components that contribute to healing at the site of transplantation. Such a membrane when transplanted has the added benefit of the absence of immune rejection due to the lack of most of the major histocompatibility (HLA) antigens and viable cells.
- Described herein are human tissue grafts derived from the placenta comprised of the amniotic membrane which is processed using physiologic solutions, lyophilization and terminal sterilization (via gamma irradiation in a frozen state) that thereby preserves the graft in such a manner as to retain the naturally occurring biological properties of the amniotic membrane and offer a sterile graft for transplantation. By dehydration via lyophilization and terminal sterilization, the graft has the advantage of storage at ambient temperatures for prolonged periods of time prior to transplantation. The advantage of this invention is that it solves the problem existing for the cryopreserved grafts, namely, the need for refrigeration or frozen storage of the graft in a wet state. This invention also solves the problem existing for the heat/chemical dried grafts, namely, the deprived biological properties remaining in a graft that has been dehydrated using heat and chemicals and/or the removal of the epithelium layer. The advantages of the invention will be realized by practice of the aspects of the description and claims subsequently described. It is to be understood that both the foregoing general description and the following detailed description are illustrative and exemplary only and are not restrictive.
- The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate the following aspects.
-
FIG. 1 is a process overview flowchart for the recovery and manufacture of the tissue grafts described herein. -
FIG. 2 is an exemplary histological representation sketch of the layers of the tissue grafts. - First it is to be understood that the aspects of the methods to be described are not limited to specific compounds, exact methods described or uses as such may vary.
FIG. 1 depicts a process overview flowchart for the recovery and manufacture of the tissue grafts described herein. - Step 1: Informed Consent Obtained, Donor Pre-Screened for Eligibility and Suitability
- Initially, the potential female donor is approached and written informed consent is obtained following standard industry practices and the guidelines set forth by AATB. The potential donor must fully understand the donation process and give their informed consent to the process and to the testing of their blood for diseases that may affect the suitability of their placenta tissues for use.
- After written consent is obtained, the donor is pre-screened for eligibility and suitability to donate her placenta at delivery. Screening involves assessment for risk factors to communicable diseases as specified in the Food and Drug Administration's (FDA) Donor Eligibility Guidance documents and regulations for Good Tissue Practices (GTP) for human tissue products intended for human transplantation. Additionally, standards put forth by the American Association of Tissue Banks (AATB) are also used as guidelines for donor eligibility criteria. After initial pre-screening information is reviewed, a determination is made as to whether the donor is eligible to donate and plans are made for the recovery of the placenta upon delivery.
- Step 2: Recover Placenta for Donor Meeting Pre-Screening Criteria
- The recovery of the placenta takes place in a hospital or birthing center where it is collected during a live Cesarean section or vaginal delivery birth. The placenta is recovered by the operating room or delivery personnel and placed in sterile designated containers, labeled with distinct donor identification information. The packaged placenta is then either shipped on wet or dry ice to the processing facility or it is temporarily stored in a freezer until it can be shipped to the processing facility.
- Step 3: Test Donor Blood for Infectious Diseases per Criteria
- Blood samples are drawn from the donor within 7 days before or after delivery and sent to a CLIA accredited contract laboratory to be tested for communicable diseases such as hepatitis, AIDS, Syphilis, and West Nile Virus using FDA licensed test kits, where appropriate. The specific list of tests for these communicable diseases that are performed are per the current FDA Donor Eligibility and GTP requirements and per AATB's standards.
- Step 4: Inspect & Release Placenta If/When All Critiera Met
- The placenta container is inspected at the processing facility upon receipt. All donor medical history charts are compiled and reviewed to include completed behavioral, sexual, medical, clinical, and health questionnaires, results of serology testing for communicable diseases, pre-natal history and medical records and hospital/birthing center delivery records. Once all donor criteria are met, the placenta is released for processing.
- Step 5: Process Tissue to Separate Amnion
- The placenta is thawed (if previously frozen) in a controlled environment and all processing methods are conducted in a controlled environment following FDA's GTP and AATB standards. Equipment and the facilities used are cleaned and decontaminated and all major processing steps are documented following industry practice, FDA regulations and AATB standards. Critical processes are validated per FDA requirements. Work areas are draped prior to usage and supplies and instruments are either sterile or clean with known manufacturing methods to control incoming bioburden.
- The placenta is inspected for abnormalities and pre-processing samples are taken to determine the baseline Bioburden. Placentas passing inspection are further processed by separating the amnion layers from both sides of the placenta from the chorion layers and the rest of the placenta. The isolated amnion layers in the form of continuous sheets of tissue are then further processed.
- Step 6: Soak, Rinse & Clean Amnion with Physiologic Saline Solutions
- The isolated amnion sheets are further processed by briefly soaking for up to 1 hour at room temperature in a physiologic saline solution such as Earle's Balanced Salt Solution (1×) or Hank's Balanced Salt Solution (1×) with periodic gentle mixing to disassociate blood from the amnion. During this time, multiple subsequent rinses with Earle's or Hank's, as needed, may be performed to further remove the blood during the soak time. During or upon completion of the soak and rinse processes, any remaining blood clots or blood on the surface of the amnion may be manually removed. The resultant amnion sheets are now ready for lyophilization.
- Step 7: Lyophilize (Freeze Dry)
- The amnion sheets are spread out on parchment paper with the stromal side face down, placed on lyophilization trays, placed in sealed lyophilization bags and lyophilized at approximately −40 to −45° C. for 20-48 hours using standard lyophilization methods until moisture is removed and desired drying is achieved. Freeze dry time may vary depending on the thickness of the tissue and the size of the amnion sheets.
- Step 8: Cut, Section & Package
- The freeze dried (lyophilized) amnion sheets are sectioned into desired sizes (e.g. 4 cm×4 cm, 4 cm×6 cm, etc.) using any sharp cutting device (e.g. a scalpel, a device similar to a pizza cutter, etc.), packaged and sealed (e.g. heat sealed, vacuum sealed, etc.).
- Step 9: Inspect & Test
- Routine quality inspections of each unit are performed to ensure that manufacturing criteria are met in the areas of size, appearance, package integrity, etc. Standard residual moisture tests may be performed on random units to ensure consistency of the freeze drying process.
- Step 10: Sterilize—Gamma Irradiate Amniotic Membrane While Frozen
- The lyophilized amnion products are shipped to a contract sterilizer to be gamma irradiated by a validated method to achieve a Sterility Assurance Level (SAL) of 10-6. The gamma irradiation is performed on dry ice with product in the frozen state to circumvent damage to the tissue. Sterilized product is returned to the possession of the processor for a final inspection.
- Step 11: Final Inspection
- Sterilized product returned from the contract sterilizer is inspected at by the processing facility for final release. Inspection will include package integrity inspection and final labeling inspection, to name a few. Units passing inspection are released for storage, distribution and subsequent transplantation.
Claims (16)
1-12. (canceled)
13. A tissue graft comprising a freeze dried human amniotic membrane, said amniotic membrane comprising the following layers in the following order:
a) a first epithelium layer,
b) a second basement membrane layer, and
c) a third stroma layer comprising an upper compact layer, a middle fibroblast layer, and a lower spongy layer.
14. The tissue graft of claim 13 , wherein said amniotic membrane contains naturally occurring growth factors and a collagen matrix.
15. The tissue graft of claim 13 , having a thickness ranging from 60-150 microns.
16. A method of repairing tissues in a patient, said method comprising wrapping or replacing a damaged tissue with the tissue graft of claims 13 .
17. The method of claim 16 , wherein said damaged tissue is a damaged tendon, damaged oral tissue, damaged gastrointestinal mucosa, damaged epidermal tissue, damaged cardiac tissue, damaged arterial tissue or damaged venous tissue.
18. A method of repairing tissues in a patient, said method comprising wrapping or replacing a damaged tissue with the tissue graft of claims 14 .
19. The method of claim 18 , wherein said damaged tissue is a damaged tendon, damaged oral tissue, damaged gastrointestinal mucosa, damaged epidermal tissue, damaged cardiac tissue, damaged arterial tissue or damaged venous tissue.
20. A method of repairing tissues in a patient, said method comprising wrapping or replacing a damaged tissue with the tissue graft of claims 15 .
21. The method of claim 20 , wherein said damaged tissue is a damaged tendon, damaged oral tissue, damaged gastrointestinal mucosa, damaged epidermal tissue, damaged cardiac tissue, damaged arterial tissue or damaged venous tissue.
22. A method for preparing a tissue graft, comprising the steps:
a) obtaining human placental tissue;
b) separating amniotic membrane from said placental tissue;
c) cleaning said separated amniotic membrane;
d) lyophilizing said cleaned amniotic membrane; and
e) packaging said lyophilized amniotic membrane to provide a tissue graft.
23. The method of claim 22 , further comprising sterilizing said amniotic membrane.
24. The method of claim 22 , wherein the amniotic membrane is terminally sterilized using gamma irradiation while frozen.
25. The method of claim 22 , wherein the amniotic membrane is cleaned with a physiologic saline solution.
26. The method of claim 22 , wherein the placenta or amniotic membrane is tested for infectious disease before proceeding.
27. The method of claim 22 , further comprising sectioning said amniotic membrane before packaging.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/608,475 US20140186461A1 (en) | 2012-09-10 | 2012-09-10 | Human Amniotic Membrane Lyophilized Grafts |
US14/801,747 US9808492B2 (en) | 2012-09-10 | 2015-07-16 | Methods of preparing lyophilized human tissues |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/608,475 US20140186461A1 (en) | 2012-09-10 | 2012-09-10 | Human Amniotic Membrane Lyophilized Grafts |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/801,747 Continuation US9808492B2 (en) | 2012-09-10 | 2015-07-16 | Methods of preparing lyophilized human tissues |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140186461A1 true US20140186461A1 (en) | 2014-07-03 |
Family
ID=51017458
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/608,475 Abandoned US20140186461A1 (en) | 2012-09-10 | 2012-09-10 | Human Amniotic Membrane Lyophilized Grafts |
US14/801,747 Active US9808492B2 (en) | 2012-09-10 | 2015-07-16 | Methods of preparing lyophilized human tissues |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/801,747 Active US9808492B2 (en) | 2012-09-10 | 2015-07-16 | Methods of preparing lyophilized human tissues |
Country Status (1)
Country | Link |
---|---|
US (2) | US20140186461A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104189955A (en) * | 2014-08-08 | 2014-12-10 | 苗九昌 | Degradable endocranium repair stent compounded by human amniotic membrane and bull dorsal aponeurosis and preparation method of repair stent |
US20150017255A1 (en) * | 2013-01-18 | 2015-01-15 | Mimedx Group, Inc. | Methods for treating cardiac conditions |
CN104998294A (en) * | 2015-08-03 | 2015-10-28 | 罗静峰 | Method for preparing medical dressings used for sterilization and hemostasis |
WO2016109826A1 (en) * | 2014-12-31 | 2016-07-07 | Applied Biologics, Llc | Standardized amniotic membrane tissue graft |
US10314688B2 (en) | 2016-08-24 | 2019-06-11 | Arthrex, Inc. | Tissue use for repair of injury |
US11116871B2 (en) | 2015-09-17 | 2021-09-14 | Stimlabs Llc | Compositions derived from placenta and methods of producing the same |
US11154641B2 (en) | 2017-12-22 | 2021-10-26 | Stimlabs Llc | Translucent, dehydrated placental tissue and methods of producing and using the same |
CN114712562A (en) * | 2022-04-08 | 2022-07-08 | 上海亚朋生物技术有限公司 | A kind of preparation technology of acellular freeze-dried amniotic membrane product |
US11413372B2 (en) | 2015-09-17 | 2022-08-16 | Stimlabs Llc | Compositions derived from placenta and methods of producing the same |
US11511017B2 (en) | 2019-03-12 | 2022-11-29 | Arthrex, Inc. | Ligament reconstruction |
WO2025133826A1 (en) * | 2023-12-18 | 2025-06-26 | Osiris Therapeutics, Inc. | Compositions and methods of making lyophilized birth tissues |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1933852B1 (en) | 2005-09-27 | 2018-12-19 | TissueTech, Inc. | Amniotic membrane preparations and purified compositions and methods of use |
EP2717888B1 (en) | 2011-06-10 | 2020-09-09 | Tissuetech, Inc. | Methods of processing fetal support tissues |
TW201603818A (en) | 2014-06-03 | 2016-02-01 | 組織科技股份有限公司 | Compositions and methods |
US20160243288A1 (en) | 2015-02-23 | 2016-08-25 | Tissuetech, Inc. | Apparatuses and methods for treating ophthalmic diseases and disorders |
US10342831B2 (en) | 2015-05-20 | 2019-07-09 | Tissuetech, Inc. | Composition and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells |
TW201733600A (en) | 2016-01-29 | 2017-10-01 | 帝聖工業公司 | Fetal support tissue products and methods of use |
US20190365948A1 (en) * | 2017-01-27 | 2019-12-05 | Aziyo Biologics, Inc. | Lyophilized placental composite sheet and uses thereof |
CN110946879B (en) * | 2018-09-26 | 2021-05-11 | 成都清科生物科技有限公司 | Acellular biological amniotic membrane containing loose layer and preparation method thereof |
WO2021173650A1 (en) | 2020-02-28 | 2021-09-02 | Aziyo Biologics Inc. | Placental tissue compositions and methods |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8372437B2 (en) | 2006-08-17 | 2013-02-12 | Mimedx Group, Inc. | Placental tissue grafts |
US8357403B2 (en) | 2007-09-07 | 2013-01-22 | Mimedx Group, Inc. | Placental tissue grafts |
EP2349364B1 (en) | 2008-10-09 | 2017-04-12 | MiMedx Group, Inc. | Methods of making collagen fiber medical constructs and related medical constructs, including nerve guides and patches |
CA2798712C (en) | 2010-05-17 | 2018-07-17 | Mimedx, Inc. | Compressible tubes for placing implants and related medical kits and methods of using same |
CA2855880C (en) | 2011-11-02 | 2021-01-05 | Mimedx Group, Inc. | Implantable collagen devices and related methods and systems of making same |
EP2785360B1 (en) | 2011-12-02 | 2019-06-19 | MIMEDX Group Inc. | Placental tissue grafts produced by chemical dehydration/freeze-drying and methods for making and using same |
JP6254094B2 (en) | 2011-12-22 | 2017-12-27 | ミメディクス グループ インコーポレイテッド | Cross-linked dehydrated placental tissue graft and methods of making and using the same |
US9180145B2 (en) | 2012-10-12 | 2015-11-10 | Mimedx Group, Inc. | Compositions and methods for recruiting and localizing stem cells |
US8946163B2 (en) | 2012-11-19 | 2015-02-03 | Mimedx Group, Inc. | Cross-linked collagen comprising metallic anticancer agents |
US9155799B2 (en) | 2012-11-19 | 2015-10-13 | Mimedx Group, Inc. | Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent |
US8940684B2 (en) | 2012-11-19 | 2015-01-27 | Mimedx Group, Inc. | Cross-linked collagen comprising an antifungal agent |
-
2012
- 2012-09-10 US US13/608,475 patent/US20140186461A1/en not_active Abandoned
-
2015
- 2015-07-16 US US14/801,747 patent/US9808492B2/en active Active
Non-Patent Citations (4)
Title |
---|
Allen et al. PLOS ONE, 8(10), e78441: 1-15. * |
Burgos et al. J R Soc Med, 1983, 76:433. * |
Niknejad et al. European Cells and Materials, 2008, 15:88-99. * |
Sekiyama et al. Investigative Ophthelmology & Visual Science, 2007, 48(4):1528-1534. * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11648281B2 (en) | 2013-01-18 | 2023-05-16 | Mimedx Group, Inc. | Methods for treating cardiac conditions |
US11000553B2 (en) | 2013-01-18 | 2021-05-11 | Mimedx Group, Inc. | Placental tissue composition for for treating cardiac tissue damage |
US20150238540A1 (en) * | 2013-01-18 | 2015-08-27 | Thomas J. Koob | Methods for treating cardiac conditions |
US20150017255A1 (en) * | 2013-01-18 | 2015-01-15 | Mimedx Group, Inc. | Methods for treating cardiac conditions |
US9662355B2 (en) * | 2013-01-18 | 2017-05-30 | Mimedx Group, Inc. | Methods for treating cardiac conditions |
US10111910B2 (en) * | 2013-01-18 | 2018-10-30 | Mimedx Group, Inc. | Methods for treating cardiac conditions |
CN104189955A (en) * | 2014-08-08 | 2014-12-10 | 苗九昌 | Degradable endocranium repair stent compounded by human amniotic membrane and bull dorsal aponeurosis and preparation method of repair stent |
WO2016109826A1 (en) * | 2014-12-31 | 2016-07-07 | Applied Biologics, Llc | Standardized amniotic membrane tissue graft |
CN104998294A (en) * | 2015-08-03 | 2015-10-28 | 罗静峰 | Method for preparing medical dressings used for sterilization and hemostasis |
US12064530B2 (en) | 2015-09-17 | 2024-08-20 | Stimlabs Llc | Compositions derived from placenta and methods of producing the same |
US11116871B2 (en) | 2015-09-17 | 2021-09-14 | Stimlabs Llc | Compositions derived from placenta and methods of producing the same |
US11413372B2 (en) | 2015-09-17 | 2022-08-16 | Stimlabs Llc | Compositions derived from placenta and methods of producing the same |
US10987209B2 (en) | 2016-08-24 | 2021-04-27 | Arthrex, Inc. | Tissue use for repair of injury |
US10314688B2 (en) | 2016-08-24 | 2019-06-11 | Arthrex, Inc. | Tissue use for repair of injury |
US11918453B2 (en) | 2016-08-24 | 2024-03-05 | Arthrex, Inc. | Tissue use for repair of injury |
US11154641B2 (en) | 2017-12-22 | 2021-10-26 | Stimlabs Llc | Translucent, dehydrated placental tissue and methods of producing and using the same |
US11738115B2 (en) | 2017-12-22 | 2023-08-29 | Stimlabs Llc | Translucent, dehydrated placental tissue and methods of producing and using the same |
US11744918B2 (en) | 2017-12-22 | 2023-09-05 | Stimlabs Llc | Translucent, dehydrated placental tissue and methods of producing and using the same |
US11511017B2 (en) | 2019-03-12 | 2022-11-29 | Arthrex, Inc. | Ligament reconstruction |
CN114712562A (en) * | 2022-04-08 | 2022-07-08 | 上海亚朋生物技术有限公司 | A kind of preparation technology of acellular freeze-dried amniotic membrane product |
WO2025133826A1 (en) * | 2023-12-18 | 2025-06-26 | Osiris Therapeutics, Inc. | Compositions and methods of making lyophilized birth tissues |
Also Published As
Publication number | Publication date |
---|---|
US20150320906A1 (en) | 2015-11-12 |
US9808492B2 (en) | 2017-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9808492B2 (en) | Methods of preparing lyophilized human tissues | |
US11752174B2 (en) | Placental tissue grafts and improved methods of preparing and using the same | |
JP5940095B2 (en) | Laminated tissue graft composed of Wharton Jerry and method of making and using the same | |
AU2015350244B2 (en) | Fenestration kits for making fenestrated placental tissue allografts and methods of using the same | |
AU2017206020B2 (en) | Human placental tissue graft products, methods, and apparatuses | |
US10568914B1 (en) | Human birth tissue laminate and methods of use | |
US10905798B1 (en) | Methods and compositions for the repair and replacement of connective tissue | |
US20160000968A1 (en) | Placental tissue grafts and improved methods of preparing and using the same | |
KR102514753B1 (en) | Amnion tissue grafts and methods of making and using the same | |
US10687934B2 (en) | Serous membrane for ocular surface disorders | |
JP2025511922A (en) | Lyophilized perforated placental membrane tissue grafts | |
US20250051723A1 (en) | Pourable placental collagen matrix sheet | |
US20160287750A1 (en) | Standardized amniotic membrane tissue graft | |
PL233525B1 (en) | Transplant and method of the transplant preparation for regeneration of tissue, preferably within the oral cavity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |